DeepTek’s chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest
DeepTek.ai, medical imaging AI company in India has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its chest X-ray AI solution – CXR Analyser. This technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorises, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations.
DeepTek’s chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It’s compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful. This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases.
Dr Amit Kharat, Co-Founder, DeepTek.ai quoted, “DeepTek CXR Analyzer v1.0 is a game-changer, reducing radiologist workload by an impressive 30-50 per cent. With FDA clearance, we’re not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we’re unlocking a world of possibilities for improved outcomes across various medical specialties.”